JUNO THERAPEUTICS
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
JUNO THERAPEUTICS
Industry:
Biotechnology Clinical Trials Health Care Medical Therapeutics
Founded:
2013-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.junotherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+1 206-696-0703
Email Addresses:
[email protected]
Total Funding:
310 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail IPv6 Microsoft Azure DNS DoubleClick.Net Amazon Virginia Region Amazon Route 53
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-07-14 | RedoxTherapies | RedoxTherapies acquired by Juno Therapeutics | N/A |
| 2016-06-22 | Contura | Contura acquired by Juno Therapeutics | N/A |
| 2016-01-11 | AbVitro | AbVitro acquired by Juno Therapeutics | 125 M USD |
| 2015-06-02 | X BODY | X BODY acquired by Juno Therapeutics | 44 M USD |
| 2015-05-12 | Stage Cell Therapeutics | Stage Cell Therapeutics acquired by Juno Therapeutics | 22 M USD |
Investors List
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Juno Therapeutics
Bezos Expeditions
Bezos Expeditions investment in Series B - Juno Therapeutics
Venrock
Venrock investment in Series B - Juno Therapeutics
Alaska Permanent Fund
Alaska Permanent Fund investment in Series B - Juno Therapeutics
Venrock
Venrock investment in Series A - Juno Therapeutics
Bezos Expeditions
Bezos Expeditions investment in Series A - Juno Therapeutics
Alaska Permanent Fund
Alaska Permanent Fund investment in Series A - Juno Therapeutics
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Juno Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-06-11 | JW Therapeutics | Juno Therapeutics investment in Series B - JW Therapeutics | 100 M USD |
| 2018-03-07 | JW Therapeutics | Juno Therapeutics investment in Series A - JW Therapeutics | 90 M USD |
| 2015-05-27 | Editas Medicine | Juno Therapeutics investment in Funding Round - Editas Medicine | 47 M USD |
Newest Events participated
Official Site Inspections
http://www.junotherapeutics.com
- Host name: 165.89.235.72
- IP address: 165.89.235.72
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Juno Therapeutics"
Juno Therapeutics - Crunchbase Company Profile
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.See details»
Juno Therapeutics, Inc. - LinkedIn
Juno Therapeutics, Inc. | 27,822 followers on LinkedIn. We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver ...See details»
Juno Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Juno Therapeutics, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Juno Therapeutics 2025 Company Profile: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for Juno Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Juno Therapeutics - Profile
May 15, 2018 Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle …See details»
Juno Therapeutics Company Profile - Craft
Juno Therapeutics $111.87 m in annual revenue in FY 2017. See insights on Juno Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Juno Therapeutics - Company Profile - Tracxn
Feb 8, 2025 Juno Therapeutics - CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer.. Acquired by Celgene. Raised a total funding of $317M over 5 rounds …See details»
Juno Therapeutics - VentureRadar
Acquired/Merged "Juno is a clinical stage company that brings together innovative technologies from three of the world's leading cancer centers ' Fred Hutchinson Cancer Research Center, …See details»
Organization | Juno Therapeutics, Inc.
Mergers & Acquisitions Historical Acquisition Tree Alternative names Early Clinical Development | Juno | Juno Therapeutics, a Subsidiary of Celgene | Juno Therapeutics, Inc. | …See details»
Juno Therapeutics (USA) Funding: $310M - medicalstartups.org
5 days ago Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen …See details»
Juno Therapeutics, Inc.:Company Profile & Technical …
Juno Therapeutics, Inc. is a company that provides Immunotherapy, Clinical trial, Medicine and more. Juno Therapeutics, Inc. is headquartered in United States Washington. Juno …See details»
Juno Therapeutics - Company info. interviews, news
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and …See details»
Juno Therapeutics - Alchetron, The Free Social Encyclopedia
Dec 20, 2023 Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial SloanKettering …See details»
Juno Therapeutics Inc. | Insights
Other Names/Subsidiaries AbVitro, Inc. Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH) JW Biotechnology (Shanghai) Co., Ltd RedoxTherapies, Inc. X-BODY, Inc.See details»
Juno Therapeutics - VentureRadar
Juno is a clinical stage company that brings together innovative technologies from three of the world's leading cancer centers ' Fred Hutchinson Cancer Research Center, Memorial Sloan …See details»
Juno Therapeutics CEO and Key Executive Team - Craft.co
Juno Therapeutics's CEO is Hans Bishop. Other executives include Hyam Levitsky, EVP, Chief Scientific Officer; Steve Harr, CFO & Head of Corporate Development and 4 others. See the …See details»
Juno Therapeutics Revenue, Growth & Competitor Profile
Mar 17, 2025 Juno Therapeutics's Annual Report & Profile shows critical firmographic facts: What is the company's size? (Annual sales and employees) Juno Therapeutics's annual …See details»
Juno Therapeutics, Inc. (Juno Therapeutics, Inc.) - 药物管线_专利_ …
了解Juno Therapeutics, Inc. (Juno Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的33项临床试验, 149篇新闻和22篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，免疫系 …See details»
Sutro Biopharma Announces Strategic Portfolio Review Resulting …
Mar 13, 2025 Astellas: Two research and development programs are ongoing with Astellas for dual-payload immunostimulatory ADCs (iADCs). These collaborations remain a strategic …See details»